Morgan Stanley Initiates Coverage on Cytek Biosciences with Equal Weight Rating and $6 Price Target
Morgan Stanley assumed coverage of Cytek Biosciences with an Equal Weight rating and a price target of $6, up from $4. Life Science Tools and Diagnostics end market bright spots are beginning to emerge and the firm sees "plenty of catalysts" in the pipeline across its coverage, adding that it sees "lots to like in the space entering 2026." However, a recent industry valuation spike in the second half of the year leaves multiples in "a fair place," so the firm starts the group with an In-Line industry view, the analyst tells investors. Among the group, the analyst identifies Danaher (DHR) as Top Pick.
Trade with 70% Backtested Accuracy
Analyst Views on CTKB
About CTKB
About the author
Cytek Biosciences (CTKB) Projects $201 Million Revenue for 2025 with Q4 Growth of 8%
- Full Year Revenue Outlook: Cytek Biosciences anticipates total revenue of approximately $201 million for 2025, indicating sustained growth potential in the biosciences sector and reflecting strong market demand.
- Q4 Performance: The company projects fourth-quarter revenue of about $62 million for 2025, representing an 8% increase compared to Q4 2024, demonstrating its competitive strength in the market for products and services.
- Earnings Report Plans: Cytek plans to report its fourth-quarter financial results and provide 2026 guidance during an earnings call expected at the end of February 2026, highlighting its commitment to transparency and investor communication.
- Stock Price Reaction: Cytek Biosciences shares rose 9.7% in pre-market trading on Nasdaq, reaching $5.98, reflecting positive market sentiment regarding its earnings outlook.
Cytek Biosciences Reports $201 Million Revenue for 2025, Q4 Growth of 8%
- Annual Revenue Outlook: Cytek Biosciences anticipates total revenue of approximately $201 million for 2025, showcasing strong performance in the cell analysis solutions market and reflecting its competitiveness in the rapidly growing biotechnology sector.
- Significant Quarterly Growth: The expected revenue for Q4 2025 is approximately $62 million, representing an 8% increase compared to Q4 2024 and a 19% increase from Q3 2025, indicating sustained strong growth in services and reagents.
- Regional Market Recovery: Cytek's instrument sales in the EMEA region returned to positive growth in Q4, demonstrating the company's ability to recover in global markets and further solidifying its position internationally.
- Positive Future Outlook: The company plans to provide 2026 financial guidance during its earnings call expected at the end of February 2026, indicating confidence in sustainable growth and profitability, particularly in the potential of the flow cytometry market.
Cytek Biosciences Reports $201 Million Revenue for 2025, Q4 Growth of 8%
- Annual Revenue Expectation: Cytek Biosciences anticipates total revenue of approximately $201 million for 2025, showcasing strong performance in the cell analysis solutions market and reflecting its competitiveness in the rapidly growing biotech sector.
- Q4 Growth: The expected revenue for Q4 2025 is around $62 million, representing an 8% increase compared to Q4 2024 and a 19% increase from Q3 2025, indicating sustained strong growth in services, reagents, and instrument sales in the Asia-Pacific region.
- Positive Market Trends: CEO Wenbin Jiang noted that the revenue growth in Q4 reflects a positive rebound in instrument sales in the EMEA region, indicating the company's potential for sustainable growth in the global flow cytometry market.
- Future Outlook: Cytek plans to report its financial results for 2025 and provide guidance for 2026 during its earnings call expected at the end of February 2026, demonstrating confidence in future growth and strategic planning.
Major Stocks Including Legence, Cidara Therapeutics, Avadel Pharmaceuticals, and Omeros Rise on Friday
U.S. Stock Market Performance: U.S. stocks declined, with the Dow Jones index dropping over 500 points on Friday, while Legence Corp's shares rose 10.7% despite mixed earnings results.
Legence Corp Earnings Report: Legence Corp reported a revenue increase of 26.2% year-over-year to $708.01 million, but missed earnings expectations with a loss of 2 cents per share.
Significant Stock Gains: Cidara Therapeutics saw a 105.6% increase after being acquired by Merck, while other companies like Invivyd Inc and Scholar Rock also experienced notable gains following positive financial results.
Other Notable Performers: Several stocks, including Avadel Pharmaceuticals and Beyond Meat, recorded gains due to various factors such as unsolicited proposals and financial announcements.
TIME Names Cytek® Biosciences Among America's Growth Leaders for 2026
Cytek Biosciences Recognition: Cytek Biosciences has been named one of TIME's America's Growth Leaders for 2026, highlighting its exceptional growth, financial stability, and stock performance over the past five years.
Innovative Technology: The company is recognized for its Full Spectrum Profiling™ (FSP®) technology, which enhances flow cytometry and supports advancements in cancer research, cell and gene therapies, and vaccine development.
Commitment to Accessibility: Cytek aims to make high-parameter cell analysis more accessible and cost-effective for laboratories of all sizes, reflecting its dedication to advancing human health and scientific understanding.
Global Impact: Cytek's FSP systems are referenced in over 3,200 peer-reviewed publications, demonstrating their significant influence on research and the broader scientific community.
Medtech Stocks Surge in After-Hours Trading: RxSight, Penumbra, and Evolus Take the Lead
RxSight's After-Hours Surge: RxSight shares jumped 18.1% after reporting a wider net loss and a 14% revenue decline, but improved its full-year revenue guidance and gross margin outlook.
Penumbra's Strong Performance: Penumbra's stock rose 16.4% following a strong Q3 with increased net income and revenue, along with a raised full-year revenue forecast.
Evolus Continues Gains: Evolus saw a 13.5% increase in after-hours trading after narrowing its net loss and reporting revenue growth, while reaffirming its full-year revenue guidance.
Modest Growth for Other Companies: CVRx and Cytek Biosciences also experienced after-hours gains, with CVRx reporting a slight improvement in losses and revenue growth, while Cytek reaffirmed its future revenue guidance despite a net loss.
Cytek Biosciences (CTKB) Projects $201 Million Revenue for 2025 with Q4 Growth of 8%
- Full Year Revenue Outlook: Cytek Biosciences anticipates total revenue of approximately $201 million for 2025, indicating sustained growth potential in the biosciences sector and reflecting strong market demand.
- Q4 Performance: The company projects fourth-quarter revenue of about $62 million for 2025, representing an 8% increase compared to Q4 2024, demonstrating its competitive strength in the market for products and services.
- Earnings Report Plans: Cytek plans to report its fourth-quarter financial results and provide 2026 guidance during an earnings call expected at the end of February 2026, highlighting its commitment to transparency and investor communication.
- Stock Price Reaction: Cytek Biosciences shares rose 9.7% in pre-market trading on Nasdaq, reaching $5.98, reflecting positive market sentiment regarding its earnings outlook.
Cytek Biosciences Reports $201 Million Revenue for 2025, Q4 Growth of 8%
- Annual Revenue Outlook: Cytek Biosciences anticipates total revenue of approximately $201 million for 2025, showcasing strong performance in the cell analysis solutions market and reflecting its competitiveness in the rapidly growing biotechnology sector.
- Significant Quarterly Growth: The expected revenue for Q4 2025 is approximately $62 million, representing an 8% increase compared to Q4 2024 and a 19% increase from Q3 2025, indicating sustained strong growth in services and reagents.
- Regional Market Recovery: Cytek's instrument sales in the EMEA region returned to positive growth in Q4, demonstrating the company's ability to recover in global markets and further solidifying its position internationally.
- Positive Future Outlook: The company plans to provide 2026 financial guidance during its earnings call expected at the end of February 2026, indicating confidence in sustainable growth and profitability, particularly in the potential of the flow cytometry market.
Cytek Biosciences Reports $201 Million Revenue for 2025, Q4 Growth of 8%
- Annual Revenue Expectation: Cytek Biosciences anticipates total revenue of approximately $201 million for 2025, showcasing strong performance in the cell analysis solutions market and reflecting its competitiveness in the rapidly growing biotech sector.
- Q4 Growth: The expected revenue for Q4 2025 is around $62 million, representing an 8% increase compared to Q4 2024 and a 19% increase from Q3 2025, indicating sustained strong growth in services, reagents, and instrument sales in the Asia-Pacific region.
- Positive Market Trends: CEO Wenbin Jiang noted that the revenue growth in Q4 reflects a positive rebound in instrument sales in the EMEA region, indicating the company's potential for sustainable growth in the global flow cytometry market.
- Future Outlook: Cytek plans to report its financial results for 2025 and provide guidance for 2026 during its earnings call expected at the end of February 2026, demonstrating confidence in future growth and strategic planning.
Major Stocks Including Legence, Cidara Therapeutics, Avadel Pharmaceuticals, and Omeros Rise on Friday
U.S. Stock Market Performance: U.S. stocks declined, with the Dow Jones index dropping over 500 points on Friday, while Legence Corp's shares rose 10.7% despite mixed earnings results.
Legence Corp Earnings Report: Legence Corp reported a revenue increase of 26.2% year-over-year to $708.01 million, but missed earnings expectations with a loss of 2 cents per share.
Significant Stock Gains: Cidara Therapeutics saw a 105.6% increase after being acquired by Merck, while other companies like Invivyd Inc and Scholar Rock also experienced notable gains following positive financial results.
Other Notable Performers: Several stocks, including Avadel Pharmaceuticals and Beyond Meat, recorded gains due to various factors such as unsolicited proposals and financial announcements.
TIME Names Cytek® Biosciences Among America's Growth Leaders for 2026
Cytek Biosciences Recognition: Cytek Biosciences has been named one of TIME's America's Growth Leaders for 2026, highlighting its exceptional growth, financial stability, and stock performance over the past five years.
Innovative Technology: The company is recognized for its Full Spectrum Profiling™ (FSP®) technology, which enhances flow cytometry and supports advancements in cancer research, cell and gene therapies, and vaccine development.
Commitment to Accessibility: Cytek aims to make high-parameter cell analysis more accessible and cost-effective for laboratories of all sizes, reflecting its dedication to advancing human health and scientific understanding.
Global Impact: Cytek's FSP systems are referenced in over 3,200 peer-reviewed publications, demonstrating their significant influence on research and the broader scientific community.
Medtech Stocks Surge in After-Hours Trading: RxSight, Penumbra, and Evolus Take the Lead
RxSight's After-Hours Surge: RxSight shares jumped 18.1% after reporting a wider net loss and a 14% revenue decline, but improved its full-year revenue guidance and gross margin outlook.
Penumbra's Strong Performance: Penumbra's stock rose 16.4% following a strong Q3 with increased net income and revenue, along with a raised full-year revenue forecast.
Evolus Continues Gains: Evolus saw a 13.5% increase in after-hours trading after narrowing its net loss and reporting revenue growth, while reaffirming its full-year revenue guidance.
Modest Growth for Other Companies: CVRx and Cytek Biosciences also experienced after-hours gains, with CVRx reporting a slight improvement in losses and revenue growth, while Cytek reaffirmed its future revenue guidance despite a net loss.
